Yoichiro Kino

Kawabe, 8691298, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

iEvac-Z, an Inactivated Ebola Vaccine - Phase 1 Study in Japan.

iEvac-Z, an Inactivated Ebola Vaccine - Phase 1 Study in Japan.

Journal: The New England journal of medicine

Published: July 29, 2026

Corrigendum to "Establishment of an analyzing method for a Japanese encephalitis virus neutralization test in Vero cells" [Vaccine 21(17-18) (2003) 1989-1994].

Corrigendum to "Establishment of an analyzing method for a Japanese encephalitis virus neutralization test in Vero cells" [Vaccine 21(17-18) (2003) 1989-1994].

Journal: Vaccine

Published: July 09, 2025

Assessing the pyrogenicity of whole influenza virus particle vaccine in cynomolgus macaques.

Assessing the pyrogenicity of whole influenza virus particle vaccine in cynomolgus macaques.

Journal: Vaccine

Published: December 28, 2021

Corrigendum to: Phase II and III Clinical Studies of Diphtheria-Tetanus-Acellular Pertussis Vaccine Containing Inactivated Polio Vaccine Derived from Sabin Strains (DTaP-sIPV).

Corrigendum to: Phase II and III Clinical Studies of Diphtheria-Tetanus-Acellular Pertussis Vaccine Containing Inactivated Polio Vaccine Derived from Sabin Strains (DTaP-sIPV).

Journal: The Journal of infectious diseases

Published: September 22, 2021

Potent priming by inactivated whole influenza virus particle vaccines is linked to viral RNA uptake into antigen presenting cells.

Potent priming by inactivated whole influenza virus particle vaccines is linked to viral RNA uptake into antigen presenting cells.

Journal: Vaccine

Published: December 07, 2020

Immune profiling of influenza-specific B- and T-cell responses in macaques using flow cytometry-based assays.

Immune profiling of influenza-specific B- and T-cell responses in macaques using flow cytometry-based assays.

Journal: Immunology and cell biology

Published: June 12, 2020

Clinical phase II and III studies of an AS03-adjuvanted H5N1 influenza vaccine produced in an EB66® cell culture platform.

Clinical phase II and III studies of an AS03-adjuvanted H5N1 influenza vaccine produced in an EB66® cell culture platform.

Journal: Influenza and other respiratory viruses

Published: November 09, 2018

Inactivated whole virus particle vaccine with potent immunogenicity and limited IL-6 induction is ideal for influenza.

Inactivated whole virus particle vaccine with potent immunogenicity and limited IL-6 induction is ideal for influenza.

Journal: Vaccine

Published: November 05, 2018

Symposium report of the 19th annual meeting of the Japanese Society for Vaccinology 2015: What is the role of clinicians in vaccinology?

Symposium report of the 19th annual meeting of the Japanese Society for Vaccinology 2015: What is the role of clinicians in vaccinology?

Journal: Vaccine

Published: March 17, 2016

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.

Journal: Microbiology and immunology

Published: May 28, 2015

A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03.

A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03.

Journal: Vaccine

Published: March 02, 2015

Highly increased levels of IgE antibodies to vaccine components in children with influenza vaccine-associated anaphylaxis.

Highly increased levels of IgE antibodies to vaccine components in children with influenza vaccine-associated anaphylaxis.

Journal: The Journal of allergy and clinical immunology

Published: February 15, 2015

Showing 1-12 of 19

Last Updated: 09/26/2026